Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : HLS Therapeutics
Deal Size : $5.0 million
Deal Type : Licensing Agreement
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL and NEXLIZET in Canada
Details : HLS Therapeutics for the exclusive rights to commercialize Nexletol and Nexlizet in Canada for cardiovascular disease.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 08, 2025
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : HLS Therapeutics
Deal Size : $5.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esperion Aligns with FDA to Initiate Phase 3 for Pediatric Hypercholesterolemia
Details : Nexlizet (bempedoic acid and ezetimibe) is in clinical development for Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : CSL
Deal Size : $5.0 million
Deal Type : Licensing Agreement
Esperion Partners with CSL Seqirus to Commercialize Nexletol and Nexlizet in Australia
Details : CSL Seqirus gains exclusive rights to commercialize Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Australia and New Zealand for cardiovascular disease.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 03, 2025
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : CSL
Deal Size : $5.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Neopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Esperion Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel
Details : Neopharm Israel gains exclusive rights to commercialize Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Israel for cardiovascular disease.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Neopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esperion Announces New Drug Submissions in Canada for Nexletol and Nexlizet
Details : Nexlizet (bempedoic acid and ezetimibe) is indicated as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia in adults.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks
Details : Nexletol(bempedoic acid) is an adenosine triphosphate-citrate lyase inhibitor indicated as an adjunct to diet and statin therapy for heart attack, hypercholesterolaemia & cardiovascular diseases.
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2024
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : $1,255.0 million
Deal Type : Collaboration
Esperion and Daiichi Sankyo Amend $125M Collaboration, Resolve Litigation
Details : The collaboration combines Esperion Therapeutics’ NILEMDO (bempedoic acid), an ACL inhibitor, with Daiichi Sankyo’s commercial capabilities for cardiovascular medicines.
Product Name : Nilemdo
Product Type : Other Small Molecule
Upfront Cash : $30.0 million
March 01, 2024
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : $1,255.0 million
Deal Type : Collaboration
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Updated Label for Bempedoic Acid, Ezetimibe Tablets
Details : Nexlizet (bempedoic acid and ezetimibe) is indicated as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia in adults.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nexletol (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL
Details : NEXLETOL (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2022
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable